Onkaido Therapeutics Inc.

Moderna Therapeutics says it has found ways to design, manufacture, formulate, and deliver mRNA so that it can instruct cells in different tissues and organs to make virtually any protein, intracellular or secreted. To begin commercializing drugs designed to make therapeutic proteins inside patients' own cells, Moderna has spun out Onkaido Therapeutics Inc. and funded it with $20 million and 15 oncology drug candidates, in the areas of apoptosis, central regulatory nodes, and immunotherapy.